Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (603707.SS)
Nanjing, CN
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of drugs and APIs in China. It also provides heparin sodium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, atracurium besylate, cisatracurium, calcium folinate, doxorubicin, milrinone, bleomycin, carboplatin, cytarabine, topotecan hydrochloride, phenylephrine hydrochloride, ganirelix acetate, furosemide, glycopyrrolate, neostigmine methylsulfate, succinylcholine chloride, reganosin, isoflurane blue, clofarabine, haloperidol decanoate, busulfan, gemcitabine hydrochloride, dexmedetomidine hydrochloride, nelarabine, rocuronium bromide, zoledronic acid, bupivacaine hydrochloride, plerixafor, eptifibatide, fondaparinux sodium, docetaxel, fluorouracil, palonosetron hydrochloride, oxaliplatin, fulvestrant, and adalimumab injections. The company offers bortezomib, bendamustine hydrochloride, mycophenolate mofetil, vancomycin hydrochloride, daptomycin, decitabine, voriconazole, tigecycline, melphalan hydrochloride, actinomycin, micafungin, azacitidine, pantoprazole sodium, mitomycin, pemetrexed disodium, thiotepa, and dacarbazine for injections. Its injection products cover anticoagulation, anti-tumor, cardiovascular disease, as well as surgical anesthesia, anti-bacterial infection, and angiography. The company was founded in 2000 and is headquartered in Nanjing, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.87% | -1.09% | -8.63% | -7.80% | -11.56% | +0.78% | -15.11% | -36.10% | -64.00% | +225.00% | +225.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+1.2% Q1'26: +4.9% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-28.0% Q1'26: +0.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+24.7% Q1'26: +51.4% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+18.3% ★ Q1'26: +10.4% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+9.3% ★ Q1'26: +5.6% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-2.2% ★ Q1'26: +5.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×2.42× ★ Q1'26: 6.90× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.11B
est: 1.06B (+4.6%)
|
1.70B
est: 1.71B (-0.8%)
|
2.47B
est: 2.44B (+1.1%)
|
2.91B
est: 3.17B (-8.1%)
|
3.69B
est: 3.88B (-4.9%)
|
3.71B
est: 3.88B (-4.3%)
|
3.93B
est: 3.77B (+4.3%)
|
3.92B
est: 4.15B (-5.4%)
|
3.97B
est: 3.90B (+1.8%)
|
4.51B
4.47B – 4.55B
+15.6% YoY
|
5.28B
4.62B – 6.26B
+17.1% YoY
|
5.97B
5.97B – 5.97B
+13.0% YoY
|
| EBITDA |
382.26M
est: 268.74M (+42.2%)
|
491.23M
est: 433.14M (+13.4%)
|
717.39M
est: 617.31M (+16.2%)
|
1.01B
est: 801.33M (+26.4%)
|
1.32B
est: 980.11M (+35.2%)
|
1.16B
est: 980.24M (+18.4%)
|
-178.25M
est: 875.34M (-120.4%)
|
1.14B
est: 962.87M (+17.9%)
|
971.32M
est: 905.43M (+7.3%)
|
1.05B
1.04B – 1.06B
+15.6% YoY
|
1.23B
1.07B – 1.45B
+17.1% YoY
|
1.39B
1.39B – 1.39B
+13.0% YoY
|
| EBIT |
341.33M
est: 231.54M (+47.4%)
|
451.37M
est: 373.17M (+21.0%)
|
672.40M
est: 531.84M (+26.4%)
|
927.95M
est: 690.38M (+34.4%)
|
1.23B
est: 844.41M (+45.9%)
|
1.02B
est: 844.52M (+21.0%)
|
-332.31M
est: 719.12M (-146.2%)
|
963.27M
est: 791.03M (+21.8%)
|
728.21M
est: 743.84M (-2.1%)
|
860.24M
853.15M – 867.33M
+15.6% YoY
|
1.01B
881.48M – 1.19B
+17.1% YoY
|
1.14B
1.14B – 1.14B
+13.0% YoY
|
| Net Income |
314.22M
est: 330.64M (-5.0%)
|
424.55M
est: 454.13M (-6.5%)
|
604.96M
est: 623.97M (-3.0%)
|
806.12M
est: 879.91M (-8.4%)
|
1.06B
est: 1.16B (-8.9%)
|
1.09B
est: 1.21B (-10.2%)
|
-189.45M
est: -408.93M (+53.7%)
|
826.14M
est: 929.98M (-11.2%)
|
581.54M
est: 858.44M (-32.3%)
|
759.40M
613.84M – 888.46M
-11.5% YoY
|
1.22B
625.02M – 1.29B
+60.6% YoY
|
1.19B
1.02B – 1.36B
-2.0% YoY
|
| SGA |
92.75M
est: 167.59M (-44.7%)
|
285.10M
est: 270.11M (+5.5%)
|
419.30M
est: 384.97M (+8.9%)
|
550.10M
est: 499.72M (+10.1%)
|
606.05M
est: 611.22M (-0.8%)
|
617.61M
est: 611.30M (+1.0%)
|
566.47M
est: 542.15M (+4.5%)
|
488.13M
est: 596.37M (-18.1%)
|
475.35M
est: 560.79M (-15.2%)
|
648.54M
643.20M – 653.89M
+15.6% YoY
|
759.41M
664.56M – 899.81M
+17.1% YoY
|
858.09M
858.09M – 858.09M
+13.0% YoY
|
| EPS |
0.21
est: 0.20 (+4.9%)
|
0.35
est: 0.27 (+27.3%)
|
0.38
est: 0.38 (+1.8%)
|
0.51
est: 0.53 (-4.2%)
|
0.67
est: 0.70 (-4.8%)
|
0.68
est: 0.74 (-7.5%)
|
-0.12
est: -0.26 (+53.4%)
|
0.51
est: 0.56 (-9.5%)
|
0.36
est: 0.52 (-30.8%)
|
0.47
0.38 – 0.55
-10.6% YoY
|
0.58
0.39 – 0.80
+23.7% YoY
|
0.74
0.63 – 0.84
+27.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETF EMCR | 0.01% | 6.6K | 0.15% |
| 2 | Franklin FTSE China ETF FLCH | 0.01% | 14.6K | 0.19% |
| 3 | Franklin FTSE China UCITS ETF FLXC.L | 0.00% | 63.7K | 0.19% |
| 4 | FlexShares Morningstar Emerging Markets Factor Tilt Index Fund TLTE | 0.00% | 9.9K | 0.58% |
| 5 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 42.1K | 0.46% |
| 6 | Schwab Emerging Markets Equity ETF SCHE | 0.00% | 145.9K | 0.06% |
| 7 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 13.7K | 0.48% |
| 8 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 30.9K | 0.26% |
| 9 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 89.2K | 0.39% |
| 10 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.53M | 0.06% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Huang Xiwei | Deputy GM, Secretary & Director | — | male |
| Tang Yongqun | GM & Chairman | — | male |
| Wu Guiping | Deputy General Manager | — | female |
| Xiaojie Qian | Financial Manager | — | female |
| Xiaomei Gu | Accounting Supervisor | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 603707.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
